MASSDEVICE ON CALL — When Johnson & Johnson (NYSE:JNJ) agreed to a $2.5 billion settlement to close some 8,000 cases over its metal-on-metal hip implants, about 1/3 of that money went to the lawyers and legal teams representing the cases.
Lawyers took an average of $90,000 of each patient’s $250,000 award, according to a New York Times report, a hefty cut that has some patients irked about the value that their legal representation brought to their cases. One patient told the Times that he estimates that his lawyer did less than $4,000 worth of work, gathering medical records and paying legal fees.
Law offices ramped up their internet and television marketing in the weeks and months preceding Johnson & Johnson’s DePuy ASR hip implant lawsuit, some gathering hundreds of claims.
The 33% cut has some patients up in arms and refusing to accept the settlement, especially those whose award was lowered due to the length of time that they had the implant or by other limiting factors such as age and weight, according to the report.
Healthcare giant Johnson & Johnson confirmed earlier this month that it agreed to a $2.5 billion settlement to close the books on one of the multi-patient lawsuits over recalled metal-on-metal hip implants made by subsidiary DePuy Orthopaedics.
The settlement closes a major chapter, but the story is far from over. There remain some 4,000 other lawsuits over the metal-on-metal hip replacement systems and patient advocacy groups want more than compensation; they want tighter oversight of the medical device industry.
The mHealth diabetes revolution begins
There’s a lot of room and opportunity in the mHealth space, especially for programs that cater to the extensive U.S. diabetic population, but separating the wheat from the chaff poses a new challenge.
FDA’s cleared more than 100 medical apps so far
The FDA has cleared 103 mobile medical apps so far, all of them through the less-stringent Class I and Class II review pathways, according to a MobiHealthNews analysis.
23andMe fallout: Is a mail-order DNA test a medical device?
The FDA’s decision to shut down consumer DNA testing provider 23andMe has met with some amount of backlash against both the FDA and against the company.
Most U.S. families unaffected by Obamacare, poll finds
A Gallup poll of U.S. families finds that 69% report that Obamacare has no direct effect on them or their families, while 9% say they’ve been helped by the reforms and 19% say they’ve been hurt by it.